Crosstalk Between the Oncoproteins of High‐Risk Human Papillomaviruses Types 16 and 18 in Colorectal Cancer Cell Models
Cancer Reports · 2025
DOI: 10.1002/cnr2.70197 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Queenie Fernandes und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, QU Health, Qatar University, Doha, Qatar. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Oncogene Proteins, Viral, Human papillomavirus 16, Human papillomavirus 18. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar University.
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) represents a major fraction of the total cancer burden worldwide. It has been recently identified that various high‐risk Human Papillomaviruses (HPVs) are present in human CRCs, where they play a critical role in the development and progression of the cancer.
Aims
In this study, we explored the synergistic effect of the E6/E7 viral oncoproteins of the two most frequently observed HPV types (16 and 18) on KRAS and TP53 mutant CRC cell models.
Methods
We performed an experimental in vitro study utilizing lipofection to transfect KRAS and TP53 mutant CRC cell models (HCT 116 and HT‐29 respectively) with E6/E7 oncoproteins of HPV types 16 and 18 individually and in combination. Subsequently, we assessed their synergistic effect on cell proliferation, invasion, migration, and survival. In addition, we also compared the protein expression patterns of key epithelial‐mesenchymal transition (EMT) biomarkers like E‐cadherin, fascin, and vimentin among transfected, co‐transfected, and wild‐type cells.
Results
We found that the co‐expression of E6/E7 of HPV types 16 and 18 enhanced cell proliferation, invasion, migration, and survival in both cell models. Interestingly, this was also accompanied by the deregulation of all three EMT biomarkers, E‐cadherin, fascin, and vimentin. The synergistic effect of the viral oncoproteins in promoting cancer was more pronounced in TP53 mutant cells (HT‐29) as compared to KRAS mutant cells (HCT 116). We also report that HPV type 18 can induce a greater and more sustained oncogenic outcome as compared to HPV type 16.
Conclusion
Our data indicate that co‐expression of the E6/E7 oncoproteins of HPV types 16 and 18 can enhance oncogenic processes in CRC, especially TP53 mutant CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Medicine, QU Health, Qatar University, Doha, Qatar.
- Translational Cancer Research Facility, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
- Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar.
- Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.
- Oncology Department, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Queenie Fernandes, Maysaloun Merhi
Förderung
- Qatar University
Zitieren
APA
Fernandes, Q., Inchakalody, V. P., Mestiri, S., Bedhiafi, T., Hydrose, S., Bashraheel, S. S., Merhi, M., Dermime, S., & Al Moustafa, A. E. (2025). Crosstalk Between the Oncoproteins of High‐Risk Human Papillomaviruses Types 16 and 18 in Colorectal Cancer Cell Models. Cancer Reports. https://doi.org/10.1002/cnr2.70197
Vancouver
Fernandes Q, Inchakalody VP, Mestiri S, Bedhiafi T, Hydrose S, Bashraheel SS, et al. Crosstalk Between the Oncoproteins of High‐Risk Human Papillomaviruses Types 16 and 18 in Colorectal Cancer Cell Models. Cancer Reports. 2025. doi:10.1002/cnr2.70197
BibTeX
@article{Fernandes2025,
author = {Fernandes, Queenie and Inchakalody, Varghese Philipose and Mestiri, Sarra and Bedhiafi, Takwa and Hydrose, Shereena and Bashraheel, Sara S and Merhi, Maysaloun and Dermime, Said and Al Moustafa, Ala-Eddin},
title = {Crosstalk Between the Oncoproteins of High‐Risk Human Papillomaviruses Types 16 and 18 in Colorectal Cancer Cell Models},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70197}
}
EUVIMED